
Novo Nordisk’s Parent Company to Increase Investments
Novo Holdings, the principal shareholder of Novo Nordisk, has shared with Financial Times their plan to annually invest 34.5 billion DKK, with a projection to reach 48.4 billion DKK by 2030. In 2023, the company spent just over 20 billion DKK on various investments. The increased ambitions are fueled by the success of Novo’s Ozempic and Wegovy, used for diabetes treatment and weight loss, respectively. According to CEO Kasim Kutay, the portfolio is growing and providing attractive returns, facilitating the largest investment budget to date. Novo Holdings recently acquired the American company Catalent for approximately 114 billion DKK, including debt. This acquisition is intended to scale up Ozempic and Wegovy production due to high demand that Novo Nordisk is struggling to meet, leading to an investment in new facilities in Kalundborg, Denmark. Consequently, the economic growth in Kalundborg was 26.9% in 2022, the highest across all municipalities in Denmark.